恶性潜能未定的黑素细胞肿瘤(MelTUMPs,包括黑素细胞瘤)的临床管理:系统综述与Meta分析
该系统综述与Meta分析检索至2021年10月,纳入111项原始研究、1962例恶性潜能未定或低度恶性潜能的黑素细胞肿瘤(MelTUMPs,包括黑素细胞瘤)患者,评估切除边缘与前端淋巴结活检(SNB)的预后价值。SNB汇总阳性率为32%(95%CI:23-44%),但复发或黑素瘤相关死亡率很低。作者认为SNB对此类肿瘤缺乏预后价值,不应常规提供SNB(高确定性证据)。
要点
- 111项研究、1962例MelTUMPs患者中,837例接受SNB,汇总阳性率为32%(95%CI:23-44%)。
- 随访1649例中,1561例(94.7%)末次评估无病存活,53例(3.2%)出现进一步疾病,29例(1.8%)死于转移性黑素瘤。
- 仅171例(已知随访者的60%)的临床结局可与切除边缘关联,未进一步分析;缺乏理想切除边缘的证据。
核心结论
- SNB在MelTUMPs中阳性率高达32%(95%CI:23-44%),但复发或黑素瘤相关死亡率很低,SNB对此类肿瘤缺乏预后价值(高确定性证据),不应常规提供SNB。
- 缺乏证据确定MelTUMPs的理想切除边缘。
研究设计与样本
- 遵循PRISMA指南的系统综述与Meta分析,检索Medline、EMBASE和Cochrane数据库至2021年10月。
- 纳入111项原始研究,报告1962例MelTUMPs患者的切除边缘和/或SNB数据。
- SNB阳性率采用随机效应模型进行Meta分析,并对亚组进行敏感性分析。
主要发现
- 1962例患者中837例接受SNB,汇总阳性率为32%(95%CI:23-44%)。
- 随访1649例中,1561例(94.7%)末次评估无病存活,53例(3.2%)出现进一步疾病,29例(1.8%)死于转移性黑素瘤,6例(0.4%)死于无关原因。
- 仅171例(已知随访者的60%)的临床结局可与切除边缘关联,因此未进一步分析。
关键数值与推荐
- SNB汇总阳性率32%(95%CI:23-44%)。
- 随访1649例中无病存活1561例(94.7%),进一步疾病53例(3.2%),黑素瘤相关死亡29例(1.8%),无关原因死亡6例(0.4%)。
临床怎么用
- 作者认为SNB不应常规用于MelTUMPs(包括黑素细胞瘤),因其对此类肿瘤缺乏预后价值(高确定性证据)。
- 作者指出缺乏证据确定MelTUMPs的理想切除边缘。
局限性
- 仅171例(已知随访者的60%)的临床结局可与切除边缘关联,因此未进一步分析切除边缘。
- 缺乏证据确定MelTUMPs的理想切除边缘。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Little guidance is currently available for managing patients with melanocytic tumours of uncertain or low malignant potential (MelTUMPs, including melanocytomas), in particular the optimal excision margins and whether to offer sentinel node biopsy (SNB). The objective of this review was to evaluate excision margins and the prognostic utility of SNB by systematic review of the literature and meta-analysis. PRISMA guidelines were followed. Medline, EMBASE and Cochrane databases were searched to October 2021 for studies of patients with MelTUMPs reporting excision margins and/or SNB-positivity. Meta-analysis was performed on the SNB-positivity rate using a random effects model, followed by sensitivity analyses on subgroups. 111 primary studies reported excision margins and/or SNB data for 1962 patients. Follow-up was available for 1649 patients: 1561 (94.7%) were alive without disease at last review, 53 (3.2%) had developed further disease, 29 (1.8%) had died of metastatic disease (melanoma) and six (0.4%) died of unrelated causes. SNB was performed in 837 patients. The pooled positivity rate on meta-analysis was 32% (95% CI: 23-44%). Clinical outcome could be correlated with excision margin in only 171 patients (60% of those with known follow up) and was therefore not analysed further. Evidence indicating the ideal excision margins for MelTUMPs was lacking. SNB had a high positivity rate despite very low rates of recurrence or melanoma-related death. Consequently, SNB should not be offered routinely for MelTUMPs (including melanocytomas), due to its lack of prognostic utility for this tumour type (high certainty of evidence).
引用
- Varey AHR, Williams GJ, Lo SN, et al. Clinical management of melanocytic tumours of uncertain malignant potential (MelTUMPs), including melanocytomas: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2022. PMID: 36251355. doi:10.1111/jdv.18665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。